CN115612486B - Cobalt/manganese dioxide quantum dot with uricase-like activity and preparation method thereof - Google Patents
Cobalt/manganese dioxide quantum dot with uricase-like activity and preparation method thereof Download PDFInfo
- Publication number
- CN115612486B CN115612486B CN202211348563.0A CN202211348563A CN115612486B CN 115612486 B CN115612486 B CN 115612486B CN 202211348563 A CN202211348563 A CN 202211348563A CN 115612486 B CN115612486 B CN 115612486B
- Authority
- CN
- China
- Prior art keywords
- cobalt
- manganese dioxide
- solution
- quantum dot
- dioxide quantum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 239000002096 quantum dot Substances 0.000 title claims abstract description 33
- 239000010941 cobalt Substances 0.000 title claims abstract description 31
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229910000428 cobalt oxide Inorganic materials 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000000694 effects Effects 0.000 title abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 31
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 19
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 19
- 229940116269 uric acid Drugs 0.000 claims description 19
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000012286 potassium permanganate Substances 0.000 claims description 9
- -1 tyrosine modified cobalt Chemical class 0.000 claims description 7
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000010525 oxidative degradation reaction Methods 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- QVKZWRGZMUGTLO-QRPNPIFTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QVKZWRGZMUGTLO-QRPNPIFTSA-N 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 abstract description 14
- 238000006243 chemical reaction Methods 0.000 abstract description 9
- 201000005569 Gout Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 230000035764 nutrition Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108010092464 Urate Oxidase Proteins 0.000 description 8
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 5
- 239000002086 nanomaterial Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001868 cobalt Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000000024 high-resolution transmission electron micrograph Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002106 nanomesh Substances 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/60—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing iron, cobalt or nickel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Materials Engineering (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a cobalt/manganese dioxide quantum dot with uricase-like activity and a preparation method thereof. The prepared cobalt/manganese dioxide quantum dot has uricase-like activity; the preparation method is simple and easy to operate, one-step synthesis and easy for mass production; the reaction condition is mild, only normal temperature and normal pressure are needed, the method is safe, pollution-free and environment-friendly, the equipment investment is less, the cost is low, and the repeatability is good; the amino acid has high safety, good heat stability and high nutrition and functionality; the obtained product has the characteristics of no toxicity, good biocompatibility, simple purification and storage, good stability, high catalytic activity and the like, and has important significance for treating diseases related to human hyperuricemia (such as gout).
Description
Technical Field
The invention relates to the field of nano biotechnology, in particular to cobalt/manganese dioxide quantum dots with uricase-like activity and a preparation method thereof.
Background
In recent years, with the development of nanomaterials, some nanomaterials have been found to have catalytic activity similar to that of natural enzymes. These nanomaterials overcome the disadvantages of easy inactivation of natural enzymes, high price, complex preparation, etc., and are therefore defined as "nanomesh". The nano enzyme has the characteristics of high catalytic activity, good stability, easy preservation, low cost and the like, and has good application prospect in the fields of food safety, biosensing, disease diagnosis and treatment and the like. Numerous nanoezymes have been developed to treat a variety of diseases, including Alzheimer's disease, inflammation, tumors, and Parkinson's disease, with relatively little research on gout. Gout is a common inflammatory arthritis caused by uric acid deposition that can lead to severe joint deformity and disability. Uric acid levels in humans are higher than in most mammals due to the lack of uricase in humans. Therefore, the development of an effective and safe novel gout treatment method has profound significance. It is for this purpose that we have sought to find a suitable catalyst to replace uricase in humans to catalyze the oxidative degradation of uric acid.
Among the metal oxide nanoenzymes, manganese dioxide nanoenzyme has activities such as a similar oxidase, a similar superoxide dismutase, a similar peroxidase, and the like. The catalytic performance of nano-enzymes is generally related to factors such as composition, structure and size, and manganese dioxide is widely studied because of adjustable particle size, various shapes and various crystal forms. By doping transition metal into the manganese dioxide nano enzyme, more oxygen vacancies are generated, so that the electron characteristic effect of the manganese dioxide is enhanced to influence the physical and chemical properties of the material, and the catalytic activity of the nano enzyme is further improved. The potential effect of cobalt/manganese dioxide in nano medicine can be further exerted by regulating the structure and the surface property of the cobalt/manganese dioxide. Quantum Dots (QDs) as an excellent fluorescent nanomaterial have been widely studied because of their high luminous efficiency and optical adjustability, as well as their wide excitation range and good optical stability.
Disclosure of Invention
In view of the above, the present invention aims to provide a method for preparing cobalt/manganese dioxide quantum dots with uricase-like activity. According to the invention, tyrosine is used as a modifier and a stabilizer to prepare the cobalt/manganese dioxide quantum dot nano-enzyme with a network structure, and the nano-enzyme has high-efficiency uricase-like activity.
The technical solution for realizing the purpose of the invention is as follows: a tyrosine-stabilized cobalt/manganese dioxide quantum dot and a preparation method thereof, wherein potassium permanganate is used as a metal precursor, tyrosine is used as a reducing agent and a modifier to stabilize and induce the cobalt/manganese dioxide quantum dot to form a network structure. The method comprises the following specific steps:
(1) Regulating the pH value of the tyrosine water solution to 10-11;
(2) Slowly dripping a freshly prepared cobalt chloride solution into the solution in the step 1), and stirring for a period of time to obtain a mixed solution;
(3) Slowly dripping a freshly prepared potassium permanganate solution into the solution in the step 2), and stirring for a period of time at room temperature to obtain a tyrosine modified cobalt/manganese dioxide quantum dot solution.
Preferably, in the step (1), a sodium hydroxide solution of 1M is adopted to adjust the pH value to 10-11.
Preferably, in the step (1), the concentration of the aqueous solution of tyrosine is 1-2.5 mg/mL.
Preferably, in the step (2), the concentration of cobalt chloride in the mixed solution is 0.5-3.0. 3.0 mM.
Preferably, in the step (2), the mixed solution is prepared by stirring for 0.5-2 hours under the condition of 1200-1500 r/min.
Preferably, in the step (3), the concentration of potassium permanganate in the tyrosine modified cobalt/manganese dioxide quantum dot solution is 0.5-1.5 mM.
Preferably, in the step (3), stirring is carried out for 0.5-2 hours under the condition of 1200-1500 r/min.
Compared with the prior art, the invention has the following advantages:
(1) Firstly, synthesizing cobalt/manganese dioxide quantum dots from bottom to top by a liquid phase reduction method;
(2) The preparation method is simple, easy to operate and suitable for mass production;
(3) The reaction condition is mild, safe and pollution-free, the equipment investment is low, and the repeatability is good;
(4) The synthesized cobalt/manganese dioxide quantum dot nano-enzyme has catalysis and fluorescence characteristics, and provides more information for reasonable design of the high-performance multifunctional nano-enzyme.
Drawings
Fig. 1 is a TEM image of cobalt/manganese dioxide quantum dots prepared in example 1.
Fig. 2 is an HRTEM image of cobalt/manganese dioxide quantum dots prepared in example 1.
FIG. 3 is a time-dependent ultraviolet-visible spectrum of catalytic uric acid oxidative degradation of cobalt/manganese dioxide quantum dots prepared in example 1.
FIG. 4 is a graph of percent oxidative degradation versus time for catalytic degradation of uric acid by cobalt/manganese dioxide quantum dots prepared in example 1.
FIG. 5 is an ultraviolet-visible spectrum of catalytic uric acid oxidative degradation of cobalt/manganese dioxide quantum dots prepared in example 2.
Detailed Description
According to the invention, potassium permanganate is used as a metal precursor, tyrosine is used as a reducing agent and a protecting agent, and cobalt/manganese dioxide quantum dots are synthesized in one-step liquid phase at room temperature under an alkaline condition. The synthesized cobalt/manganese dioxide quantum dot has uricase catalytic activity, fluorescence performance and catechol oxidase catalytic performance, and provides more information for reasonable design of high-performance multifunctional nano enzyme. The synthesized cobalt/manganese dioxide quantum dot has uric acid oxidase mimic enzyme to catalyze and degrade uric acid, and provides a new choice for treating gout.
Compared with the disclosed invention: the invention overcomes the problems of high price of noble metal, low catalytic performance, easy poisoning and the like of platinum nanoclusters with uric acid family-like activity and a preparation method thereof (CN 1203280A), and the prepared cobalt/manganese dioxide quantum dot nano enzyme has the characteristics of low price, fluorescence performance, excellent catalytic performance, stability, and the like.
Example 1
Preparation of tyrosine modified cobalt/manganese dioxide quantum dots
In the first step, 18.2mg of tyrosine powder is dispersed in 8.9 mL ultrapure water at 25 ℃, and the pH value of the solution is adjusted to 11 by using 1M sodium hydroxide solution, so that the tyrosine is completely dissolved; secondly, slowly dripping 0.1 mL freshly prepared 0.1M cobalt chloride aqueous solution into the pH-adjusted tyrosine solution, and continuously stirring at 1500 r/min for reaction of 0.5 h; and thirdly, slowly dripping 1 mL freshly prepared 10 mM potassium permanganate solution into the solution in the second step, continuously stirring and reacting at 1500 r/min for 0.5 h, and preparing the tyrosine modified cobalt/manganese dioxide quantum dot, and storing at 4 ℃ for later use.
TEM image, HRTEM image and time-dependent ultraviolet-visible spectrum of the prepared cobalt/manganese dioxide quantum dot and catalytic uric acid oxidative degradation are shown in figures 1-3. As can be seen from FIG. 1, co/Tyr-MnO 2 QDs are not discrete particles, but rather small particles assembled to form a network-like structure. Co/Tyr-MnO shown in FIG. 2 2 The lattice spacing of QDs is 0.21 and 0.24 and nm, which correspond to gamma-MnO respectively 2 (300) Crystal face and (131) crystal. The characteristic absorption peak of uric acid at 292 nm in FIG. 3 gradually decreases with time until it disappears, indicating Co/Tyr-MnO 2 QDs are capable of catalyzing the rapid oxidation of uric acid in the human environment (pH 7.4, 37 ℃).
Example 2
Preparation of tyrosine modified cobalt/manganese dioxide quantum dots
In the first step, 18.2mg of tyrosine powder is dispersed in 8.9 mL ultrapure water at 25 ℃, and the pH value of the solution is adjusted to 11 by using 1M sodium hydroxide solution, so that the tyrosine is completely dissolved; secondly, slowly dripping 0.2 mL of freshly prepared 0.1M cobalt chloride aqueous solution into the pH-adjusted tyrosine solution, and continuously stirring 1500 r/min for reaction 1 h; and thirdly, slowly dripping 1 mL freshly prepared 10 mM potassium permanganate solution into the solution in the second step, continuously stirring and reacting for 1 h at 1500 r/min to prepare the tyrosine modified cobalt/manganese dioxide quantum dot, and storing at 4 ℃ for later use.
Example 3
Determination of uricase Activity of tyrosine-modified cobalt/manganese dioxide Quantum dots
120. Mu.L of the network-like cobalt/manganese dioxide quantum dot prepared in example 1 above was added to 2850. Mu.L of 50mM PBS buffer, then 30. Mu.L of 5mM uric acid solution was added thereto, the final reaction solution had a volume of 3 mL, and the reaction was carried out at 37℃for 46 minutes, whereby the ultraviolet-visible spectrum of the system was measured at 2-minute intervals. As shown in FIG. 3, the characteristic absorption peak of uric acid at 290 nm in the spectrum gradually decreases with time, indicating that the uric acid has good uricase activity. FIG. 4 shows that catalytic degradation of uric acid corresponds to the first order reaction.
Example 4
Determination of uricase Activity of tyrosine-modified cobalt/manganese dioxide Quantum dots
120. Mu.L of the network-like cobalt/manganese dioxide quantum dot prepared in example 2 above was added to 2850. Mu.L of 50mM PBS buffer, then 30. Mu.L of 5mM uric acid solution was added thereto, the final reaction solution had a volume of 3 mL, and the reaction was carried out at 37℃for 40 minutes to determine the ultraviolet-visible spectrum of the system. As shown in FIG. 5, the characteristic absorption peak of uric acid at 290 and nm in the spectrogram is obviously reduced with time, which indicates that the uricase has good uricase activity.
Claims (6)
1. The preparation method of the cobalt/manganese dioxide quantum dot is characterized by taking potassium permanganate as a metal precursor, tyrosine as a reducing agent and a modifier to stabilize and induce the cobalt/manganese dioxide quantum dot to form a network structure, and comprises the following specific steps of:
(1) Regulating the pH value of the tyrosine water solution to 10-11;
(2) Slowly dripping a freshly prepared cobalt chloride solution into the solution in the step (1), and stirring for a period of time to obtain a mixed solution;
(3) Slowly dripping a freshly prepared potassium permanganate solution into the solution in the step (2), and stirring for a period of time at room temperature to obtain a cobalt/manganese dioxide quantum dot solution;
in the step (1), the concentration of the tyrosine aqueous solution is 1-2.5 mg/mL;
in the step (2), the concentration of the cobalt chloride in the mixed solution is 0.5-3.0 mM;
in the step (3), the concentration of potassium permanganate in the tyrosine modified cobalt/manganese dioxide quantum dot solution is 0.5-1.5 mM.
2. The method of claim 1, wherein in step (1), the pH is adjusted to 10 to 11 using 1M sodium hydroxide solution.
3. The method of claim 1, wherein in the step (2), the mixed solution is prepared by stirring for 0.5 to 2 hours under the condition of 1200 to 1500 r/min.
4. The method of claim 1, wherein in step (3), the stirring is performed at 1200 to 1500 r/min for 0.5 to 2 hours.
5. The cobalt/manganese dioxide quantum dot prepared by the method of any one of claims 1 to 4, wherein the cobalt/manganese dioxide quantum dot has a network structure.
6. Use of cobalt/manganese dioxide quantum dots prepared by the method of any one of claims 1-4 for catalyzing oxidative degradation of uric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211348563.0A CN115612486B (en) | 2022-10-31 | 2022-10-31 | Cobalt/manganese dioxide quantum dot with uricase-like activity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211348563.0A CN115612486B (en) | 2022-10-31 | 2022-10-31 | Cobalt/manganese dioxide quantum dot with uricase-like activity and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115612486A CN115612486A (en) | 2023-01-17 |
| CN115612486B true CN115612486B (en) | 2024-02-13 |
Family
ID=84876885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211348563.0A Active CN115612486B (en) | 2022-10-31 | 2022-10-31 | Cobalt/manganese dioxide quantum dot with uricase-like activity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115612486B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015047079A2 (en) * | 2013-08-27 | 2015-04-02 | Sirim Berhad | Application of enzyme-quantum dots hybrid system for the determination of uric acid |
| WO2015169104A1 (en) * | 2014-05-09 | 2015-11-12 | 福州大学 | Sandwich-like manganese dioxide/polyaniline composite material and preparation method therefor |
| JP2019172487A (en) * | 2018-03-27 | 2019-10-10 | 国立大学法人山口大学 | Cobalt composite γ-type manganese dioxide and method for producing the same |
| CN111203280A (en) * | 2020-01-15 | 2020-05-29 | 扬州大学 | Platinum nanocluster with uricase activity and preparation method thereof |
-
2022
- 2022-10-31 CN CN202211348563.0A patent/CN115612486B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015047079A2 (en) * | 2013-08-27 | 2015-04-02 | Sirim Berhad | Application of enzyme-quantum dots hybrid system for the determination of uric acid |
| WO2015169104A1 (en) * | 2014-05-09 | 2015-11-12 | 福州大学 | Sandwich-like manganese dioxide/polyaniline composite material and preparation method therefor |
| JP2019172487A (en) * | 2018-03-27 | 2019-10-10 | 国立大学法人山口大学 | Cobalt composite γ-type manganese dioxide and method for producing the same |
| CN111203280A (en) * | 2020-01-15 | 2020-05-29 | 扬州大学 | Platinum nanocluster with uricase activity and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| Highly tuned cobalt‑doped MnO2 nanozyme as remarkably efficient uricase mimic;Mira V. Parmekar等;Applied Nanoscience;第10卷;317-328 * |
| Ingenious Multifunctional MnO2 Quantum Dot Nanozymes with Superior Catechol Oxidase-like Activity for Highly Selective Sensing of Redox-Active Dopamine Based on an Interfacial Passivation Strategy;Wenting Zou等;ACS Sustainable Chem. Eng.;第10卷;10057-10067 * |
| Mira V. Parmekar等.Highly tuned cobalt‑doped MnO2 nanozyme as remarkably efficient uricase mimic.Applied Nanoscience.2019,第10卷317-328. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115612486A (en) | 2023-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Du et al. | New insights into the formation mechanism of gold nanoparticles using dopamine as a reducing agent | |
| JPH07503447A (en) | Production of hydrogen peroxide | |
| JPS595012B2 (en) | Manufacturing method of platinum catalyst for fuel cell electrodes | |
| CN107159883B (en) | Chitosan-nano platinum particle simulates oxidizing ferment | |
| Ren et al. | Superoxide dismutase mimetic ability of Mn-doped ZnS QDs | |
| CN113244958B (en) | Mn-MOF cold-fit nano enzyme and preparation method and application thereof | |
| CN113135998A (en) | Preparation method of selenium-rich starch | |
| Aggarwal et al. | Zinc oxide nanoparticles-impregnated chitosan surfaces for covalent immobilization of trypsin: stability & kinetic studies | |
| Chauhan et al. | Chitosan-thiomer stabilized silver nano-composites for antimicrobial and antioxidant applications | |
| Gao et al. | Controlled preparation and application of glutathione capped gold and platinum alloy nanoclusters with high peroxidase-like activity | |
| CN115845842A (en) | Nano-diamond/graphene-loaded noble metal iridium cluster nanoenzyme as well as preparation method and application thereof | |
| CN114891354B (en) | Nano composite material based on nano enzyme cascade reaction and preparation method and application thereof | |
| CN115612486B (en) | Cobalt/manganese dioxide quantum dot with uricase-like activity and preparation method thereof | |
| CN108889303A (en) | The support type high dispersive copper-based catalysts and preparation method of carbon dioxide methanol and application | |
| CN113952984B (en) | High-catalytic-activity molybdenum-based nanoenzyme and preparation method and application thereof | |
| Moraes et al. | Development of cashew gum-based bionanocomposite as a platform for electrochemical trials | |
| CN111203280A (en) | Platinum nanocluster with uricase activity and preparation method thereof | |
| CN113084187A (en) | Preparation method and application of gold, silver and palladium three-metal peroxide mimic enzyme | |
| CN115282966B (en) | Ferrous ion doped copper cobaltate material and preparation method thereof | |
| KR102494993B1 (en) | Method for producing gold nanoparticles having increased glucose oxidase and peroxidase activities and gold nanoparticles by the method | |
| RU2423384C1 (en) | Method of preparing aqueous system for branched fractal clusters based on l-cysteine | |
| CN116650524A (en) | Preparation method of near infrared photocatalytic defect bismuth nano-sheet with acid response | |
| CN111060501A (en) | Nano cerium peroxide catalyst and method for catalyzing TMB color development by using same | |
| CN113186228B (en) | Microbial supported palladium-gold bimetallic nano-catalyst and preparation method and application thereof | |
| CN113499430A (en) | Fenton metal ion doped metal-organic framework material solidified oxidative metabolism enzyme nano diagnosis and treatment agent, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |